一种组织蛋白酶S抑制剂治疗原发性干燥综合征的随机、双盲、安慰剂对照、平行组研究
这项2A期随机双盲安慰剂对照平行组研究纳入75例原发性干燥综合征患者,按1:1随机接受RO5459072(100 mg每日两次,即每日200 mg)或安慰剂治疗12周。主要终点为ESSDAI评分较基线下降≥3分的患者比例,两组间无显著差异;所有次要结局均未观察到有利于RO5459072的临床有意义疗效。RO5459072安全且耐受性良好,生物标志物分析提示靶点结合。
要点
- RO5459072 100 mg每日两次治疗12周,ESSDAI应答率与安慰剂无显著差异。
- 所有次要结局均未观察到有利于RO5459072的临床有意义疗效。
- RO5459072安全且耐受性良好,生物标志物提示靶点结合。
核心结论
- ESSDAI评分(主要终点)无临床相关改善,任何次要临床终点均无有利于RO5459072的明显获益。
- 需要进一步工作以理解原发性干燥综合征中MHC-II介导的免疫刺激机制。
研究设计与样本
- 随机、双盲、安慰剂对照、平行组、2A期研究。
- 75例原发性干燥综合征患者按1:1随机接受RO5459072(100 mg每日两次,即每日200 mg)或安慰剂治疗12周。
- 主要终点为ESSDAI评分较基线下降≥3分的患者比例。
主要发现
- ESSDAI评分改善的患者比例在RO5459072组与安慰剂组之间无显著差异。
- 所有次要结局均未观察到有利于RO5459072的临床有意义疗效。
- 可溶性生物标志物分析提示RO5459072与组织蛋白酶S之间存在靶点结合。
- RO5459072组循环B细胞和T细胞数量有轻度下降,但未达显著性。
- RO5459072安全且耐受性良好。
关键数值与推荐
- 主要终点为ESSDAI评分较基线下降≥3分的患者比例。
- RO5459072剂量为100 mg每日两次(每日200 mg),治疗12周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步工作以理解原发性干燥综合征中MHC-II介导的免疫刺激机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Primary SS (pSS) is a chronic autoimmune disorder characterized by mucosal dryness and systemic symptoms. We tested the effects of inhibition of cathepsin S using the potent and selective inhibitor RO5459072 on disease activity and symptoms of pSS. METHODS: This was a randomized, double-blind, placebo-controlled, parallel-group, Phase IIA study to investigate the effects of RO5459072 (100 mg twice daily; 200 mg per day). Seventy-five patients with pSS were randomized 1:1 to receive either RO5459072 or placebo for 12 weeks. The primary outcome was the proportion of patients with a ≥3 point reduction from baseline in EULAR SS Disease Activity Index (ESSDAI) score. We also investigated the effects of RO5459072 on quality of life, exocrine gland function, biomarkers related to SS, and safety and tolerability. RESULTS: The proportion of patients showing an improvement in ESSDAI score was not significantly different between the RO5459072 and placebo arms. No clinically meaningful treatment effects were observed in favour of RO5459072 for all secondary outcomes. Analysis of soluble biomarkers indicated target engagement between RO5459072 and cathepsin S. There were modest decreases in the number of circulating B cells and T cells in the RO5459072 group, although these did not reach significance. RO5459072 was safe and well-tolerated. CONCLUSIONS: There was no clinically relevant improvement in ESSDAI score (primary endpoint), and no apparent benefit in favour of RO5459072 in any of the secondary clinical endpoints. Further work is needed in order to understand the mechanisms of MHC-II-mediated immune stimulation in pSS. TRIAL REGISTRATION: ClinicalTrials.gov; NCT02701985.
引用
- Bentley D, Fisher BA, Barone F, et al. A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome. Rheumatology (Oxford). 2023. PMID: 36864622. doi:10.1093/rheumatology/kead092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。